The PIVOT-02 study analyzed the use of bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab for the treatment of advanced/metastatic urothelial carcinoma (aUC). The combination provided beneficial antitumor activity in patients as a first-line treatment, and displayed benefits over immune checkpoint inhibitor monotherapy. The PIVOT-10 trial has expanded on this research by further investigating this treatment combination in cisplatin-ineligible patients with previously untreated mUC. ...
Advanced Urothelial Carcinoma
Advertisement
Latest News
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Amanda Nizam, MDGenitourinary Medical Oncologist | Cleveland Clinic
Advertisement
Get the latest UC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.